OCEA Ocean Biomedical, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1869974 · Fiscal year ends 12/31
Financial factors as of 2025-03-31 (2025Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY1.6%
TTM EPS YoY6.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-1,276.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets5,940.6%
Debt / equity—
Current ratio0.06x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.14x
Accruals ratio-1,097.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $26,000 | $709,000 |
| SG&A expense | $3.77M | $9.51M |
| Operating income | -$3.80M | -$10.21M |
| Interest expense | — | $50,000 |
| Net income | -$9.48M | -$114.47M |
| EPS (basic) | -0.34 | -4.35 |
| EPS (diluted) | -0.34 | -4.35 |
| Weighted avg. shares (diluted) | 27.50M | 26.29M |
| Banking | ||
| Net interest income | -$2.05M | -$1.76M |
| Balance sheet | ||
| Cash & equivalents | $200,000 | $4,000 |
| Current assets | $812,000 | $2.11M |
| Total assets | $902,000 | $5.50M |
| Current liabilities | $33.89M | $30.01M |
| Short-term debt | — | $3.20M |
| Total liabilities | $98.52M | $96.26M |
| Shareholders' equity | -$97.62M | -$90.76M |
| Shares outstanding | 34.87M | 34.65M |
| Cash flow statement | ||
| Operating cash flow | -$4.18M | -$9.43M |
| Financing cash flow | $3.40M | $10.40M |
| Stock-based compensation | $745,000 | $1.21M |
Free plan shows the latest 2 periods; Pro shows all 3 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.